secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001650664-25-000077
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports in vivo POC data for undisclosed liver target; ~70% editing in mice
--------------------------------------------------------------------------------

- Maximal liver editing of ~70% in disease-specific mouse model using LNP-delivered CRISPR/Cas cargo.
- Robust target protein upregulation with >80% reduction of disease-associated biomarker in mice.
- In cynomolgus monkey hepatocytes: >50% target gene editing and >15-fold protein upregulation.
- Company expects to disclose the disease target and development candidate later in 2025.
- Data presented at ASGCT Annual Meeting; additional oral presentation at TIDES USA on May 21.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000077/0001650664-25-000077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000077/edit-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer